CP 55,244 - Revision history

Prab: CSV import

2025-02-13T03:54:01Z

CSV import

← Older revision		Revision as of 03:54, 13 February 2025
Line 1:		Line 1:
	~~'''~~CP 55,244''' is a synthetic [[cannabinoid]] that was developed by the pharmaceutical company [[Pfizer]] in the 1980s. It is part of a series of related compounds that include [[CP 47,497]] and [[CP 50,556-1]]. These compounds are considered to be [[cannabinoid receptor]] agonists, meaning they bind to and activate the cannabinoid receptors in the body.		== CP-55,244 ==

	~~==Chemistry==~~		[[File:CP-55,244.svg\|thumb\|right\|Chemical structure of CP-55,244]]

	CP 55,244 is a ~~complex molecule with~~ a ~~unique structure~~. It is ~~a derivative of~~ [[~~cyclohexanol~~]], and its chemical formula is C24H40O3. The compound is characterized by a cyclohexyl group (a six-membered ring of carbon atoms) attached to a phenol group (a benzene ring with a hydroxyl group). The molecule also contains a side chain of three carbon atoms, ending in a hydroxyl group.		'''CP-55,244''' is a synthetic cannabinoid compound that acts as a potent agonist of the [[cannabinoid receptor]]s. It is primarily used in scientific research to study the [[endocannabinoid system]] and its effects on various physiological processes.

	==~~Pharmacology~~==		== Chemical Properties ==

	~~As a cannabinoid receptor agonist,~~ CP 55,244 ~~has~~ a ~~high affinity for~~ the [[~~CB1 receptor]] and [[CB2 receptor~~]], the ~~two main types of~~ cannabinoid receptors in ~~the body. These receptors are part of~~ the [[~~endocannabinoid~~ system]], ~~which plays a role in a variety~~ of ~~physiological processes~~, ~~including pain sensation~~, ~~mood~~, ~~and memory~~.		CP-55,244 is a member of the [[cannabinoid]] class of compounds, which are known for their interaction with the cannabinoid receptors in the [[central nervous system]]. The chemical structure of CP-55,244 is characterized by its complex arrangement of carbon, hydrogen, and oxygen atoms, as depicted in the adjacent image.

	~~When CP 55,244 binds to the CB1 or CB2 receptors, it mimics the effects~~ of the body's natural cannabinoids, such as [[anandamide]] and [[2-Arachidonoylglycerol\|2-AG]]. This can result in a range of effects, depending on the specific receptor and the location in the body where it is activated.		== Mechanism of Action ==

	~~==Research~~ and ~~Potential Uses==~~		CP-55,244 functions as an agonist at the [[CB1 receptor\|CB1]] and [[CB2 receptor\|CB2]] cannabinoid receptors. These receptors are part of the [[G protein-coupled receptor]] family and are involved in a variety of physiological processes, including [[pain modulation]], [[appetite regulation]], and [[immune response]].

	Research into CP 55,244 and related compounds has focused on their potential therapeutic uses. Because of their ability to activate the cannabinoid receptors, these compounds could potentially be used to treat a variety of conditions, including chronic pain, inflammation, and neurological disorders.		== Pharmacological Effects ==

	~~However~~, ~~much~~ of ~~this research is still~~ in ~~the early stages~~, and ~~more studies are needed~~ to ~~fully understand~~ the potential ~~benefits and risks~~ of ~~these compounds~~.		The activation of cannabinoid receptors by CP-55,244 leads to a range of effects, which can include alterations in [[neurotransmitter]] release, modulation of [[inflammatory response]], and changes in [[behavioral patterns]]. Due to its potency, CP-55,244 is often used in laboratory settings to explore the potential therapeutic applications of cannabinoid receptor modulation.

	==~~See Also~~==		== Research Applications ==

			CP-55,244 is utilized in [[preclinical research]] to investigate the role of the endocannabinoid system in various diseases and conditions. Studies often focus on its potential in treating [[neuropathic pain]], [[anxiety disorders]], and [[neurodegenerative diseases]].

			== Safety and Toxicology ==

			As with many synthetic cannabinoids, the safety profile of CP-55,244 is not fully understood. Research is ongoing to determine its potential [[toxicological]] effects and any long-term consequences of its use in experimental settings.

			== Related Pages ==

	* [[Cannabinoid]]
	* [[Cannabinoid receptor]]		* [[Cannabinoid receptor]]
	* [[Endocannabinoid system]]		* [[Endocannabinoid system]]
	* [[~~CP 47,497~~]]		* [[Synthetic cannabinoids]]
	* [[~~CP 50,556-1~~]]		* [[CB1 receptor]]
			* [[CB2 receptor]]
	~~==References==~~

	~~{{reflist}}~~

	[[Category:Synthetic cannabinoids]]		[[Category:Synthetic cannabinoids]]
	~~[[Category:Pfizer products]]~~
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	~~{{Pharma-stub}}~~
	~~{{No image}}~~

Prab: CSV import

2025-02-10T07:32:54Z

CSV import

← Older revision		Revision as of 07:32, 10 February 2025
Line 33:		Line 33:
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	{{Pharma-stub}}		{{Pharma-stub}}
			{{No image}}

Prab: CSV import

2024-02-28T23:33:37Z

CSV import

New page

'''CP 55,244''' is a synthetic [[cannabinoid]] that was developed by the pharmaceutical company [[Pfizer]] in the 1980s. It is part of a series of related compounds that include [[CP 47,497]] and [[CP 50,556-1]]. These compounds are considered to be [[cannabinoid receptor]] agonists, meaning they bind to and activate the cannabinoid receptors in the body.

==Chemistry==

CP 55,244 is a complex molecule with a unique structure. It is a derivative of [[cyclohexanol]], and its chemical formula is C24H40O3. The compound is characterized by a cyclohexyl group (a six-membered ring of carbon atoms) attached to a phenol group (a benzene ring with a hydroxyl group). The molecule also contains a side chain of three carbon atoms, ending in a hydroxyl group.

==Pharmacology==

As a cannabinoid receptor agonist, CP 55,244 has a high affinity for the [[CB1 receptor]] and [[CB2 receptor]], the two main types of cannabinoid receptors in the body. These receptors are part of the [[endocannabinoid system]], which plays a role in a variety of physiological processes, including pain sensation, mood, and memory.

When CP 55,244 binds to the CB1 or CB2 receptors, it mimics the effects of the body's natural cannabinoids, such as [[anandamide]] and [[2-Arachidonoylglycerol|2-AG]]. This can result in a range of effects, depending on the specific receptor and the location in the body where it is activated.

==Research and Potential Uses==

Research into CP 55,244 and related compounds has focused on their potential therapeutic uses. Because of their ability to activate the cannabinoid receptors, these compounds could potentially be used to treat a variety of conditions, including chronic pain, inflammation, and neurological disorders.

However, much of this research is still in the early stages, and more studies are needed to fully understand the potential benefits and risks of these compounds.

==See Also==

* [[Cannabinoid]]
* [[Cannabinoid receptor]]
* [[Endocannabinoid system]]
* [[CP 47,497]]
* [[CP 50,556-1]]

==References==

{{reflist}}

[[Category:Synthetic cannabinoids]]
[[Category:Pfizer products]]
[[Category:Pharmacology]]
{{Pharma-stub}}